More issues

Get Humira (Adalimumab) Approved by Blue Cross Blue Shield North Carolina: Complete Forms, Appeals & Contact Guide

Answer Box: Getting Humira Approved by BCBS North Carolina Blue Cross Blue Shield of North Carolina requires prior authorization for Humira (adalimumab) with step therapy through preferred biosimilars first. Submit PA via the Availity Provider Portal or call 800-672-7897. Include clinical documentation of biosimilar failures, diagnosis codes, and medical necessity.
6 min read

How to Get Enhertu (fam-trastuzumab deruxtecan-nxki) Covered by Blue Cross Blue Shield in New York: Complete Prior Authorization and Appeal Guide

Quick Answer: Getting Enhertu Covered by BCBS in New York Enhertu (fam-trastuzumab deruxtecan-nxki) requires prior authorization from Blue Cross Blue Shield plans in New York for HER2-positive breast cancer, NSCLC, and gastric cancer. Key requirements include documented HER2 status (IHC 3+ or ISH amplified), prior trastuzumab-based therapy failure, and NCCN
6 min read

How to Get Zolgensma (onasemnogene abeparvovec-xioi) Covered by Cigna in Illinois: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Zolgensma Covered by Cigna in Illinois Zolgensma (onasemnogene abeparvovec-xioi) requires prior authorization from Cigna for pediatric patients under 2 years with spinal muscular atrophy (SMA). Key requirements: genetic confirmation of ≤3 SMN2 copies, anti-AAV9 antibodies ≤1:50, baseline labs within 30 days, and prescription by an SMA
6 min read

How to Get Zolgensma (onasemnogene abeparvovec-xioi) Covered by Blue Cross Blue Shield in California: Prior Authorization Guide, Appeals Process, and Success Strategies

Answer Box: Fast Track to Zolgensma Coverage Blue Shield of California requires prior authorization for Zolgensma with specific clinical criteria: confirmed SMA diagnosis via genetic testing, age under 2 years, ≤3 SMN2 gene copies, and no advanced disease. Submit through AuthAccel portal with genetic documentation. If denied, file internal appeal
5 min read